INTRODUCTION
Myeloproliferative neoplasms (MPN), including primary myelofibrosis (PMF) and myelofibrosis evolving from a pre-existing MPN (post polycythemia vera-and post essential thrombocythemia-myelofibrosis), are myeloid progenitor cell-derived conditions characterized by bone marrow fibrosis, osteosclerosis and pathologic angiogenesis (1, 2) . Over the last 3 decades many therapies have been evaluated in myelofibrosis, including JAK inhibitors (e.g., ruxolitinib, fedratinib, pacritinib), immunomodulatory drugs (e.g., thalidomide, lenalidomide), DNA methyltransferase (DNMT) inhibitors (e.g., 5-azacytidine, decitabine), chemotherapeutic agents (e.g, hydroxyurea, cladribine), and biologic-response modifiers (e.g., androgens, erythropoietin) (3) . Unfortunately, no one therapy has demonstrated an ability to produce complete remissions or even rapid and consistent reversal of fibrosis in many patients with MF.
Discovery of the JAK2V617F mutation in MF, resulting in constitutive activation of the JAK-STAT pathway, led to the development of the potent and selective JAK1/2 inhibitor ruxolitinib. Ruxolitinib greatly reduces the signs and symptoms associated with MF, including reduction in spleen size, weight gain, improved performance status and control of constitutional symptoms, leading to prolonged survival; in selected patients it can, after prolonged therapy, decrease the degree of marrow fibrosis (4) (5) (6) (7) . Based on the positive outcomes in two phase III studies (COMFORT-I, COMFORT-II) (8, 9) ruxolitinib has been approved for use in patients with intermediate-or high-risk myelofibrosis in the US. While ruxolitinib significantly abrogates splenomegaly and constitutional symptoms, it has little to no effect on improving erythropoiesis in patients with MF. Furthermore, some patients achieve a less than optimal response to ruxolitinib while others lose a response after some time. Alternate therapeutic approaches, including the development of rational combinations with ruxolitinib to concurrently target other potential drivers of MF may overcome these therapeutic hurdles.
Thalidomide, lenalidomide and pomalidomide are immunomodulatory agents (IMiDs) that have demonstrated improvements in anemia, thrombocytopenia and splenomegaly in selected patients with MF (10) (11) (12) (13) (14) (15) (16) (17) (18) . Lenalidomide is a derivative of thalidomide that is more effective and less toxic than thalidomide (19) . This improved safety profile has made lenalidomide an attractive choice for combination regimens in multiple myeloma (20, 21) , myelodysplastic syndrome (MDS) (22) and high-risk MDS/acute myeloid leukemia (AML) (23, 24) . In MF, lenalidomide alone or in combination with prednisone elicits response rates of approximately 30% (13, 14, 18) , and was particularly effective at improving erythropoiesis. Furthermore, in a study of 40 patients treated with lenalidomide plus prednisone, 91% and 100% of evaluable patients who had a clinical response had reductions in bone marrow fibrosis and JAK2 allele burden, respectively (14) . These type of improvements warrant further evaluation of lenalidomide in combination with other active drugs in MF.
The combination of lenalidomide and ruxolitinib may target distinct clinical and pathological manifestations of MF as well as prevent therapy-related worsening of blood cell counts, allowing proper administration of ruxolitinib in high-risk MF patients with significant cytopenia's at presentation. Therefore, we sought to evaluate the efficacy and safety of this combination in patients with MF in a phase 2 study. To our knowledge this is the first published report of a clinical trial testing a JAK2 inhibitor in combination with another agent. they had sub-optimal benefit defined as less than 50% reduction in spleen length from baseline and/or no improvements in cytopenia. Low-dose aspirin prophylaxis was recommended for patients with platelet count > 75 x 10 9 /L to reduce thrombosis risk.
METHODS

Eligibility
Details of patient evaluation on study are included in the Supplemental Data.
Study Design
This study was designed as a two-stage (MiniMax), prospective, single center, phase II trial. The primary efficacy endpoint of the trial was IWG-MRT defined objective response rate, including complete remission (CR), partial remission (PR) or clinical improvement (CI), within the 6 months of study initiation (27) . The combination would be considered unpromising if ≤ 35% of patients achieved an objective response, which in general corresponds to the objective response rate with single-agent ruxolitinib (8, 9) . The smallest proportion of patients achieving a response that would support subsequent studies was 50%. Given the response rates stated above, if the probability of inappropriately accepting a poor therapy is 10% (alpha=0.1), a total sample size of 49 patients would result in 80% power (beta=0.2).
The study included one interim analysis after 31 evaluable patients had been observed for at least 6 months to permit early stoppage if there was strong evidence that the study regimen was inactive. If 10 or fewer patients responded to the combination therapy after being treated for 6 months or discontinued due to excessive toxicity or lack of efficacy, then the study would be terminated. Those patients who stopped receiving one of the two study drugs due to safety reasons were counted as failures in the efficacy analysis.
If 11 or more treatment successes were observed in these 31 patients, an additional 18 patients would be accrued. After 49 patients had been accrued, if 21 or fewer patients responded to the combination therapy or discontinued due to excessive toxicity, the therapy would be declared ineffective. The patients were simultaneously monitored for toxicity.
RESULTS
Thirty-one patients with primary, post-PV, or post-ET MF with anemia were enrolled.
Patient characteristics are summarized in Table 2 . Twenty-one patients (68%) had received a median of two prior therapies (range, 1-3) for MF. Eleven patients (35%) had received hydroxyurea alone, 5 (16%) had received anagrelide and hydroxyurea, 7 (23%)
had received interferon (pegylated-interferon in 3 and interferon-alpha in 4), 3 (10%) had received DNMT-inhibitors, 2 (6%) had received thalidomide, 1 had received danazol, 
Concomitant administration of ruxolitinib and lenalidomide
Simultaneous administration of ruxolitinib and lenalidomide was difficult: 23 patients required a dose interruption with or without dose decrease due to toxicity. On the other hand, 6 patients required a dose increase of one or both drugs due to lack of satisfactory efficacy. Dose-interruptions occurred early, with 20 of the 23 dose interruptions occurring within 3 months of initiation of the combination. Only 6 of these 20 patients were able to restart lenalidomide. Therefore, 14 patients (45% of all the study patients) were completely off lenalidomide within 3 months of initiation of therapy. The details of dose adjustments/interruptions and the reasons for dose adjustment/interruption are given in Table 3 .
Response to ruxolitinib and lenalidomide therapy
Twenty-five patients (81%) remain alive after a median follow-up of 28 months (range, was subsequently discontinued in all 4 patients due to myelosuppression. As these 4 patients were on the combination at the time of response it is possible that they achieved therapeutic benefit from the addition of the lenalidomide. Furthermore, these patients continue to be monitored on study. Hence, we included these patients in the response and endpoint analysis.
Although an IWG-MRT-defined response was achieved in 17 patients, only 7 patients met the predetermined definition of efficacy: response to the combination within 6 months of initiation without discontinuation of one of the study drugs. Six patients who achieved the response after 6 months and 10 patients who had discontinued lenalidomide at the time of response due to drug-related toxicities were counted as failures in accordance with the predefined efficacy analysis. Since fewer than 10 patients met the predetermined efficacy rules for treatment success the study was terminated after 31 patients.
Impact of combination therapy on response
The ability to successfully administer the combination of ruxolitinib and lenalidomide influenced the response rate. As noted in Table 3 One episode of lower extremity thrombosis was noted. Three deaths were documented (two on study and one after discontinuation of treatment) and were attributed to pneumonia in 1 patient, kidney failure in 1, and possible stroke in 1.
Of the 15 patients who have come off study, 3 were due to concurrent disease (lymphoma, emphysema, and pericarditis with renal failure, respectively), 2 who initially responded due to disease progression, 2 due to myelosuppression (grade 4 anemia and grade 3 thrombocytopenia, respectively), 3 due to refractory disease, 2 due to toxicities (grade 2 persistent nausea and grade 3 diarrhea, respectively), 1 due to persistent and severe lower extremity cellulitis, 1 due to non-compliance, and 1 for financial reasons.
Among the 16 patients that remain on study 10 are still taking both ruxolitinib and lenalidomide and 6 are taking ruxolitinib only. None of the patients are taking only lenalidomide. The ruxolitinib dose ranges from 10 mg BID to 25 mg BID continuously, and the lenalidomide dose ranges from 5 mg daily to 15 mg daily for 21 days of 28-day cycle.
DISCUSSION
In our study, the combination of lenalidomide and ruxolitinib elicited an IWG-MRT- Concomitant initiation and continuation of both drugs was difficult due to toxicity with most discontinuations occurring early when the hematological toxicities were at their peak: 2/3 of patients required interruption of either lenalidomide or both drugs within 3 months of initiation. The main reasons for early interruption were myelosuppression (70%) or GI toxicities attributable to lenalidomide (15%). In cases where the toxicity was more attributable to one agent that agent was discontinued e.g. diarrhea, DVT and skin rash more likely attributable to lenalidomide. Ruxolitinib likely plays a more central role in the treatment of myelofibrosis. Thus, when toxicities occurred that could not be clearly attributed to either of the drugs (e.g. myelosuppression) ruxolitinib was preferentially continued and lenalidomide was the first drug to be interrupted, as was done in all 23
cases that needed interruption. The specific reasons for lenalidomide and ruxolitinib interruptions are listed in Table 3 . Seventy percent of the patients who required an early interruption were unable to restart lenalidomide, resulting in 45% of the patients being treated on single-agent ruxolitinib within the first 3 months. Among the patients who did not require early interruption, 8 of 11 (73%) achieved a response, suggesting that the combination -when deliverable -might be associated with an improved response rate.
This appeared to be associated with reduction in bone marrow cellularity and LDH but, Our current experience with the lenalidomide-ruxolitinib combination teaches us that although there is likely a clinical benefit to combining other agents with JAK2 inhibitors, the cumulative or overlapping toxicities (e.g. myelosuppression), optimal dosage and treatment schedule need to be carefully evaluated. A sequential rather than concomitant approach could be considered when contemplating combination regimens with ruxolitinib, which may further increase the response rate and tolerability of such combinations. For example, a run-in phase with ruxolitinib for 3 months followed by a cautious introduction and gradual escalation of lenalidomide may have improved the tolerability and efficacy of this combination. We are currently exploring such an approach in ongoing novel combination strategies at our institution (NCT01787487, NCT02267278).
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